my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
MorphoSys AG (Neuer Markt: MOR) today announced the development and release of a new proprietary antibody library, HuCAL® GOLD. The library is to be presented at the 12th IBC Antibody Engineering conference in San Diego, California. Initial results show that the new library and related screening system lead to faster and more efficient antibody generation, as well as enabling the achievement of higher average affinity antibodies and more diverse fully human antibodies. Furthermore, the new library increases the Company's independence from several on-going patent disputes.
HuCAL® GOLD contains several significant innovations over previous versions of the HuCAL® library and is combined with the Company's proprietary CysDisplayTM screening technology. Importantly, the new library carries diverse repertoires in all six CDR regions of the underlying antibody genes, meaning that HuCAL® GOLD provides more diversity than previous versions. Moreover in combination with the CysDisplayTM
"HuCAL® GOLD is the culmination of several years of technological development of our proprietary HuCAL® platform" commented Dr. Thomas von Rueden, Chief Scientific Officer of MorphoSys AG. "We already have good evidence that its superior properties enable us to make better antibodies. Of equal importance is the fact that most of the technology underlying HuCAL® GOLD is proprietary to MorphoSys and independent of other technologies - thus the new library clarifies even further our IP position."
Sigma-Aldrich and MorphoSys AG announced a collaboration agreement to design, produce and distribute unique recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD(R) technology. MorphoSys's AbD Serotec unit will develop and qualify unique antibodies from MorphoSys's propri ... more
MorphoSys Expands Target Discovery Capability in Oridis Biomed Collaboration
MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today an Agreement with Oridis Biomed Forschungs- und Entwicklungs GmbH, Graz, Austria, that will provide MorphoSys with preferred access to one of the world’s largest human tissue banks. The goal of the collaborat ... more
MorphoSys Expands Target Discovery Capability in Oridis Biomed Collaboration
MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today that a court in San Diego has granted its motion to dismiss a second attempt by Cambridge Antibody Technology Ltd. (CAT), together with The Medical Research Council, The Scripps Research Institute and Stratag ... more
Medical Director / Medical Scientist (gn) in Clinical Development
We would like to fill the following vacancy as soon as possible: Provide medical expertise to clinical programs for tafasitamab – in the area of oncology. Focus on design, timely preparation and execution of the clinical trial(s) Prepare or oversee preparation of clinical trial protoco ... more
We would like to fill the following vacancy as soon as possible: Contributes to planning of global clinical trials and designs site management processes from study start-up to closure in collaboration with global CRO(s) and sponsor Clinical Trial Team (CTT) meeting the requirements of the ... more
Scientist Clinical Biomarkers (gn)
We would like to fill the following vacancy as soon as possible: Develop and implement clinical biomarker strategies in collaboration with clinical department Identify Contract Research Organizations (CROs) for outsourced biomarker testing in the context of clinical trials Manage C ... more
